Suppr超能文献

TAK1 在调节套细胞淋巴瘤存活中的重要作用。

Essential role of TAK1 in regulating mantle cell lymphoma survival.

机构信息

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

出版信息

Blood. 2012 Jul 12;120(2):347-55. doi: 10.1182/blood-2011-07-369397. Epub 2012 May 30.

Abstract

TGF-β-activated kinase 1 (TAK1), a member of the MAPK kinase family, plays a key role in B-cell growth and development. In the present study, we examined the potential role of TAK1 as a therapeutic target for lymphoma. Here, we show that the active phosphorylated form of TAK1 is abundantly expressed in a panel of lymphoma cell lines, including mantle cell, anaplastic large cell, and Hodgkin lymphoma cell lines. Silencing TAK1 expression via the use of siRNA inhibited the activation of NF-κB and p38 and induced apoptosis in lymphoma cell lines. Moreover, submicromolar concentrations of AZ-TAK1, a novel ATP-competitive small molecule inhibitor of TAK1, dephosphorylated TAK1, p38, and IκB-α in lymphoma cell lines. These molecular events were associated with the release of cytochrome c into the cytosol, down-regulation of X-linked inhibitor of apoptosis, activation of caspase 9, and induction of apoptosis. We also demonstrate that primary lymphoma cells express TAK1 and pTAK1 and were sensitive to AZ-TAK1-mediated cell death. Collectively, our data demonstrate an essential role for TAK1 in regulating critical survival mechanisms in lymphoma and suggest that it may serve as a therapeutic target.

摘要

转化生长因子-β激活激酶 1(TAK1)是丝裂原活化蛋白激酶激酶家族的成员,在 B 细胞的生长和发育中发挥关键作用。在本研究中,我们研究了 TAK1 作为淋巴瘤治疗靶点的潜力。结果显示,在一系列淋巴瘤细胞系中,包括套细胞淋巴瘤、间变大细胞淋巴瘤和霍奇金淋巴瘤细胞系中,TAK1 的活性磷酸化形式大量表达。通过使用 siRNA 沉默 TAK1 的表达,抑制了 NF-κB 和 p38 的激活,并诱导了淋巴瘤细胞系的凋亡。此外,新型 TAK1 的小分子抑制剂 AZ-TAK1 以亚微摩尔浓度抑制了 TAK1、p38 和 IκB-α 的磷酸化。这些分子事件与细胞色素 c 向细胞质中的释放、凋亡抑制蛋白 X 连锁的下调、半胱天冬酶 9 的激活以及凋亡的诱导有关。我们还证明原发性淋巴瘤细胞表达 TAK1 和 pTAK1,并且对 AZ-TAK1 介导的细胞死亡敏感。综上所述,我们的数据表明 TAK1 在调节淋巴瘤中关键生存机制方面发挥着重要作用,并提示其可能成为治疗靶点。

相似文献

1
Essential role of TAK1 in regulating mantle cell lymphoma survival.
Blood. 2012 Jul 12;120(2):347-55. doi: 10.1182/blood-2011-07-369397. Epub 2012 May 30.
5
Identification of TGF-β-activated kinase 1 as a possible novel target for renal cell carcinoma intervention.
Biochem Biophys Res Commun. 2014 Oct 10;453(1):106-11. doi: 10.1016/j.bbrc.2014.09.070. Epub 2014 Sep 26.
10
Cross interference with TNF-alpha-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1.
Biochim Biophys Acta. 2009 Jul;1793(7):1156-64. doi: 10.1016/j.bbamcr.2009.04.005. Epub 2009 Apr 21.

引用本文的文献

3
Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma.
EJHaem. 2023 Jul 27;4(3):667-678. doi: 10.1002/jha2.758. eCollection 2023 Aug.
5
Discovery of 2,4-1-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors.
ACS Med Chem Lett. 2021 Mar 3;12(4):555-562. doi: 10.1021/acsmedchemlett.0c00547. eCollection 2021 Apr 8.
6
Synthesis and biological activity of 2-cyanoacrylamide derivatives tethered to imidazopyridine as TAK1 inhibitors.
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1928-1936. doi: 10.1080/14756366.2020.1833876.
7
TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases.
Open Biol. 2020 Sep;10(9):200099. doi: 10.1098/rsob.200099. Epub 2020 Sep 2.
8
Structure and Characterization of a Covalent Inhibitor of Src Kinase.
Front Mol Biosci. 2020 May 19;7:81. doi: 10.3389/fmolb.2020.00081. eCollection 2020.
9
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Haematologica. 2021 May 1;106(5):1401-1413. doi: 10.3324/haematol.2019.234476.

本文引用的文献

1
In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells.
Blood. 2010 Nov 4;116(18):3505-16. doi: 10.1182/blood-2010-02-269605. Epub 2010 Aug 3.
2
X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise.
Clin Cancer Res. 2010 Sep 15;16(18):4496-502. doi: 10.1158/1078-0432.CCR-10-1664. Epub 2010 Aug 3.
3
The TAK1-TRAF6 signalling pathway.
Int J Biochem Cell Biol. 2010 May;42(5):585-9. doi: 10.1016/j.biocel.2009.12.023. Epub 2010 Jan 12.
4
Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling.
Immunol Rev. 2009 Nov;232(1):300-18. doi: 10.1111/j.1600-065X.2009.00836.x.
5
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
Mod Pathol. 2009 Oct;22(10):1312-20. doi: 10.1038/modpathol.2009.98. Epub 2009 Jul 10.
6
Smac mimetics as new cancer therapeutics.
Anticancer Drugs. 2009 Sep;20(8):646-58. doi: 10.1097/CAD.0b013e32832ced78.
7
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.
8
Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Cancer Res. 2009 Mar 15;69(6):2550-8. doi: 10.1158/0008-5472.CAN-08-1808. Epub 2009 Feb 24.
9
A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation.
Blood. 2009 May 7;113(19):4566-74. doi: 10.1182/blood-2008-08-176057. Epub 2009 Feb 5.
10
Heat shock protein 90 as a drug target: some like it hot.
Clin Cancer Res. 2009 Jan 1;15(1):9-14. doi: 10.1158/1078-0432.CCR-08-0132.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验